Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.17 $1.66 Friday, 10th May 2024 IFRX stock ended at $1.18. This is 1.67% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 6.41% from a day low at $1.17 to a day high of $1.25.
90 days $1.17 $1.92
52 weeks $1.14 $5.20

Historical InflaRx N.V. prices

Date Open High Low Close Volume
Dec 29, 2017 $20.90 $21.75 $20.40 $20.95 38 594
Dec 28, 2017 $20.45 $23.50 $20.09 $20.79 15 313
Dec 27, 2017 $22.08 $22.08 $18.60 $20.41 131 307
Dec 26, 2017 $24.19 $26.92 $21.99 $22.13 17 340
Dec 22, 2017 $21.00 $26.49 $21.00 $23.99 14 073
Dec 21, 2017 $19.71 $21.37 $19.71 $21.29 21 878
Dec 20, 2017 $19.02 $20.06 $19.01 $19.76 35 324
Dec 19, 2017 $18.14 $19.48 $18.14 $19.00 30 222
Dec 18, 2017 $18.29 $19.91 $18.29 $19.85 21 934
Dec 15, 2017 $18.50 $19.99 $17.53 $18.21 74 830
Dec 14, 2017 $18.07 $18.96 $17.95 $18.41 105 248
Dec 13, 2017 $18.10 $18.15 $17.50 $18.05 167 097
Dec 12, 2017 $18.80 $18.90 $17.95 $18.00 44 708
Dec 11, 2017 $19.43 $20.20 $18.75 $18.76 39 072
Dec 08, 2017 $18.26 $19.63 $18.26 $19.19 33 274
Dec 07, 2017 $17.44 $18.73 $17.40 $18.05 123 980
Dec 06, 2017 $18.70 $19.00 $17.01 $17.58 92 955
Dec 05, 2017 $19.07 $19.07 $17.67 $18.66 32 784
Dec 04, 2017 $21.01 $21.22 $19.24 $19.24 48 357
Dec 01, 2017 $21.67 $22.32 $20.23 $20.88 87 549
Nov 30, 2017 $20.50 $22.48 $20.50 $21.30 91 860
Nov 29, 2017 $17.80 $21.56 $17.80 $20.70 41 100
Nov 28, 2017 $16.70 $19.60 $16.70 $19.00 15 239
Nov 27, 2017 $15.23 $16.70 $15.15 $16.70 17 784
Nov 24, 2017 $14.93 $15.30 $14.93 $15.30 876
Click to get the best stock tips daily for free!

About InflaRx N.V.

InflaRx N.V. InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III c... IFRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT